Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDR001 plus dabrafenib and trametinib vs placebo plus dabrafenib and trametinib in untreated unresectable or metastatic BRAF V600 mutant melanoma
jRCT2080223604Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2017
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing PDR001 + dabrafenib + trametinib with Placebo + dabrafenib + trametinib (2 arms). Started Jul 2017; status: completed.
02
Drugs
spartalizumabdabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on jRCT2080223604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223604.